Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19.

According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%.

U.S. drugmaker Gilead Sciences reported the new data on Friday.

Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial.

There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.